+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Volibris"

Volibris - API Insight, 2022 - Product Thumbnail Image

Volibris - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Volibris- Drug Insight, 2019 - Product Thumbnail Image

Volibris- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The Volibris market is a segment of the cardiovascular drug industry that focuses on the development and commercialization of drugs for the treatment of pulmonary arterial hypertension (PAH). These drugs are designed to improve the quality of life of patients with PAH by reducing symptoms such as shortness of breath, fatigue, and chest pain. The Volibris market is composed of a variety of pharmaceutical companies, including those that specialize in the development of new drugs and those that focus on the marketing and distribution of existing drugs. The Volibris market is highly competitive, with companies competing to develop and market the most effective drugs. Companies in the market are also competing to develop new formulations of existing drugs, as well as to develop new drugs that target different aspects of PAH. Companies in the Volibris market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more